NCT00124215View on ClinicalTrials.gov

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

February 28, 2010

Conditions
Hepatitis C
Interventions
BIOLOGICAL

GI-5005

Heat-killed yeast cell transfected with NS3-Core fusion protien.

Trial Locations (5)

10021

Weill Medical College of Cornell University, New York

33136

University of Miami, Miami

60637

University of Chicago, Chicago

80262

University of Colorado Health Sciences Center, Denver

91105

Huntington Medical Research Institutes, Pasadena

Sponsors

Lead Sponsor

GlobeImmune
All Listed Sponsors
lead

GlobeImmune

INDUSTRY